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Abstract 
Risk Evaluation and Mitigation Strategies (REMS) are the most 
recent risk management initiative put forth by the Food and Drug 
Administration (FDA) that decreases the risk associated with 
certain medications. They may be mandatory by the FDA or can 
be produced voluntarily by the manufacturer in order for a drug 
associated with significant risk to be approved. REMS may 
include one or multiple elements, including a Medication Guide 
(MedGuide), Communication Plan, Elements to Assure Safe Use 
(ETASU), Implementation Plan, and Timetable for Submission 
of Assessments. Although REMS enhance patient care by 
reducing risk and maintaining patient safety, an unbalanced 
burden is placed on the health care system to implement these 
elements. A stakeholder meeting with representation from a 
variety of health care provider groups was held in October 2010, 
to discuss these issues and potential resolutions. Specific to the 
field of pharmacy, pharmacists must be aware of REMS 
requirements and how they affect medication access and patient 
care in order to maintain adequate and appropriate therapy. 
Introduction 
Risk Evaluation and Mitigation Strategies are the newest ini-
tiative in the riskmanagement program of the Food and Drug 
Administration (FDA). With the continuing development of 
new drugs come new risks associated with them. Drug manu-
facturers present risk-benefit data to the FDA as part of the 
New Drug Application (NDA), and the FDA evaluates this in-
formation during the approval process to determine neces-
sary risk management strategies for certain products. Manu-
facturers may also voluntarily provide a REMS program. Ad-
ditionally, new drug safety information is revealed after a 
drug has been on the market and used in a larger patient 
population than the small, limited population studied in clini-
cal trials. This post-marketing data may warrant developing 
or revising a REMS program. REMS programs can allow 
therapeutically beneficial drugs that present significant risks 
to be approved and marketed. 
Risk Management History 
Laws and regulations have progressed historically in order to 
keep patients safe while continuing drug approvals. Risk 
management strategies were first notably implemented in 
the 1960s, when the FDA required manufacturers to disclose 
all product information within the product labeling for health 
care professionals (HCPs) to access. In the late 1970s, Patient 
Package Inserts (PPis) were required to be provided to pa-
tients using oral contraceptives to explain the benefits and 
risks of using the product,1.2 This was significant because 
drug safety information was then being extended to patients 
for them to acknowledge and be informed about risks with 
their therapies. In the late 1990s, certain products such as 
Accutane® (isotretinoin), Clozaril® (clozapine) and Tha-
lomid® (thalidomide) were substantially beneficial medica-
tions for certain patient populations that also came with sig-
nificant risk. As a result of possible harm to the patient, 
medications like these had restricted access. After some 
medications were withdrawn from the market due to re-
ported serious side effects, there was a demand for even 
tighter risk management requirements. In response, the FDA 
provided three guidances in 2005 for risk management ini-
tiatives-Premarketing Risk Assessment, Development and 
Use of Risk Minimization Action Plans (RiskMAPs), and Good 
Pharmacovigilance Practices and Pharmacoepidemiologic 
Assessment.2 The RiskMAP guidance provided a direction for 
manufacturers to develop a program that took necessary 
actions and precautions for use of medications associated 
with certain risks. This enabled a better potential for thera-
peutically beneficial products to become approved and re-
main on the market. This risk management strategy was the 
precursor to the current REMS program. 
The REMS Era 
Similar to RiskMAPs, REMS is part of the Food and Drug Ad-
ministration Amendments Act of 2007 (FDAAA) mandated 
by Congress.2 This legislation replaced the former RiskMAP 
risk management strategy and formalized the FDA's role in 
drug development, distribution, and post-marketing commit-
ments regarding safety issues. It also allows the FDA to en-
force compliance to the program and monetarily penalize 
those who do not comply.3 Depending on the specific risks of 
the drug, a program may include one element or multiple 
elements. Manufacturers must provide a REMS program for 
the product to the FDA after notice of necessity (or voluntar-
ily), and the program must be assessed after implementation 
to determine efficacy and new safety data. The different ele-
ments that a REMS may include are listed on the following 
page (Table 1). The timetable for submission of assessment 
is the only mandatory part of a REMS. 
REMS Example: FOCUS Program for Onsolis®s 
In order to understand the complexity of a REMS program, 
an example of the Onsolis® REMS will be described in more 
detail. This program was chosen because it includes all REMS 
elements. Onsolis® (fentanyl) is an approved opioid product 
for breakthrough pain in adult cancer patients who are on 
around-the-clock opioids. The buccal film dosage form dis-
solves when it is placed on the inside of the cheek. While the 
overall goal of REMS is to mitigate risk, the specific goal of 
the Full Ongoing Commitment to User Safety (FOCUS) Pro-
gram for Onsolis® is to minimize the risk of overdose, abuse, 
addiction, and serious complications due to medication er-
rors. This will be accomplished by selecting the right pa-
tients, reducing exposure in individuals for whom it is not 
prescribed, and training providers about proper dosing and 
administration. The FOCUS Program consists of a Medication 
Guide, Communication Plan, ETASU, Implementation Plan, 
and Timetable for Submission of Assessments. 
January 2012 Volume 3, Issue 1 THE PHARMACY AND WELLNESS REVIEW 3 
REMS REMS: Risk Management Strategies, Current Issues, and the Pharmacist's Role 
Table 1. REMS Elements2,4 
Medication Guide 
(MedGuide) 
Safety information written in patient-friendly language; must be given to patient every time 
drug is dispensed 
Communication Plan Educational materials for safety and appropriate use 
Elements to Assure Safe Use 
(ETASU) 
Strict systems or requirements to enforce the appropriate use of a drug; Examples include 
the following: 
• Specialized training and/or certification of health care providers 
• Restricted distribution to limited settings 
• Evidence or documentation of safe use conditions prior to dispensing to patient 
• Registries ofprescribers, pharmacies, and/or patients 
• Patient monitoring 
Implementation Plan Description of how certain ETASUs will be implemented 
Timetable for Submission of 
Assessments 
Frequency the program must be evaluated; minimum at 18 months, 3 years, and 7 years 
after the roduct is introduced to the market 
Medication Guide 
The Medication Guide is a six-page document.6 Before dis-
pensing the medication for the first time, the prescriber must 
counsel the patient on this document. The pharmacy staff 
must also give this to the patient every time the medication is 
dispensed. 
Communication Plan 
The Communication Plan includes a two-page6 Dear Pre-
scriber Letter that was sent to HCPs at the time the product 
was put on the market. The letter introduces the product and 
provides important information about the product. 
ETASU 
The ET ASU ensures that only certified providers and phar-
macies may prescribe and dispense Onsolis®, and that the 
medication is only dispensed to patients with documentation 
of safe use conditions. In order to be certified, providers and 
pharmacies (via the pharmacist-in-charge) are educated and 
enrolled by reviewing the website or printed educational 
materials and completing the appropriate enrollment forms. 
The pharmacist must also review a Dear Pharmacist Letter. 
Prescribers and pharmacies must be re-educated and re-
enrolled at least every two years or following significant 
changes to the program. Pertaining specifically to pharmacy, 
the pharmacy agrees to comply with several actions when 
signing the enrollment form: 
1. The pharmacy staff must be trained about the pro-
gram and agree to provide the MedGuide every time 
Onsolis® is dispensed. 
2. The drug may only be dispensed after the pharmacy 
confirms that the patient has a valid prescription 
and has been counseled appropriately. 
3. The pharmacy staff will not substitute the product. 
4. The pharmacy will provide reports of Onsolis® pre-
scription activity and allow program-related audits. 
When dispensing the medication, the pharmacy must verify 
that the patient and corresponding prescriber both have an 
active status within the database. After this is fulfilled, the 
pharmacy receives a database authorization number to allow 
the dispensing process to be completed. In addition to pro-
viders, patients are also involved in the enrollment process 
and must meet safe use conditions. Each patient must be 
counseled on the product and enrolled prior to receiving his/ 
her first prescription. The prescriber counsels the patient on 
the MedGuide, the risks and benefits of the medication, and 
how to appropriately use it. The patient also receives a coun-
seling call from a FOCUS Program trained staff member. After 
these steps are completed, the patient receives a unique 
identification number for the database. Like prescribers and 
pharmacies, patients must also re-enroll every two years or 
following significant program changes. 
Implementation System 
The Implementation System describes the manufacturer's 
responsibilities for ET ASU. The manufacturer maintains and 
monitors enrolled entities via the database. The manufac-
turer also ensures that wholesalers and distributors are spe-
cially certified (also re-enrolled every two years or following 
significant program changes). The manufacturer also com-
mits to take appropriate actions in terms of non-compliance 
or if the results of the REMS program do not meet expecta-
tions. 
Timetable for Submission of Assessments 
The Timetable for Submission of Assessments is set at six 
months and one year after NDA approval date and annually 
thereafter. 
A REMS program such as this one may adequately mitigate 
risk associated with the product. However, it is evident that 
it affects the practices of providers, including physicians, 
pharmacists, distributors, and manufacturers, as well as pa-
tients. Several issues arise from these disturbances in work-
flow and access. 
Current Issues4,7,B 
Several issues are evident with current REMS programs. Al-
though the REMS program reduces risk, the number and 
complexity of the programs required by the FDA has in-
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creased, placing an unbalanced burden on the healthcare 
system. As a result, patients may not be getting the best care 
possible because access to some products may be difficult 
beyond the initial intent of REMS. REMS are generally bur-
densome and can generate administrative or staffing chal-
lenges. Providers may change prescribing habits in order to 
avoid REMS requirements (i.e. prescribing a different medi-
cation without a REMS that might be less therapeutically 
beneficial). Pharmacies may not supply certain products. 
Adding to this difficulty, no standard compensation model 
exists to make up for the extra time and resources necessary 
to fulfill requirements. Additionally, a lack of a standardiza-
tion and complication of programs may deter drug develop-
ment, while provider time and resources are being ex-
hausted. With a lack of standardization, different REMS re-
quirements may be implemented for similar medications or 
products with similar side effects. However, even with the 
implementation of risk minimizing programs, the tools are 
not as effective as they could be. Currently, MedGuides are 
the most common tools used in REMS, but these tend to be 
lengthy and unequally describe risks more than benefits of 
the medication. Many programs are initiated without partici-
pation from providers during their development. As a result, 
the program specifics are difficult to implement in primary 
care, and logistics add to the complexity for providers. If 
changes are warranted for an existing plan, it may take 
months to approve updated programs. Also, there is cur-
rently no single resource to access all REMS information and 
providers must find each program individually. All of these 
issues and challenges may ultimately lead to compromised 
patient care, including increased patient costs from the resul-
tant burden on the healthcare system and higher drug costs. 
Finally, as the industry is gearing toward the imminent 
"patent cliff' that will shift the market even more toward 
generic drugs, some brand companies may see REMS pro-
grams as a way to protect their products from generic com-
petition. It can be challenging for generic manufacturers to 
address REMS requirements in a way that is comparable to a 
brand manufacturer because REMS programs can be re-
source intensive and margins are smaller on the generic mar-
ket In addition, brand companies may use REMS programs 
to restrict access to their drugs, thereby preventing generic 
drug manufacturers from obtaining the drug in order to con-
duct bioequivalence studies required by the FDA to show 
equivalent safety and effectiveness of the generic product. 
This goes beyond the initial intent of REMS to mitigate 
patient risk. 
Stakeholder Meeting4 
In October 2010, 34 stakeholders from national health care 
provider associations (including physicians, physician assis-
tants, nurses, nurse practitioners, and pharmacists), drug 
manufacturer associations, community pharmacists, patient 
advocates, drug distributors, and health information technol-
ogy, standards, and safety organizations met to discuss the 
REMS program. The FDA was also present to observe the 
meeting. The discussions centered around improving REMS 
by maximizing safe and effective patient medication use 
while minimizing burden on the healthcare system. Sugges-
tions to accomplish this included the following: using effec-
tive risk management tools and interventions, having a stan-
dardized REMS program, allowing easy and neutral imple-
mentation of REMS programs, and outlining a model for 
proper compensation. The stakeholders discussed these is-
sues and proposed solutions to improve the REMS system. 
One of the first areas targeted was the use of effective risk 
management tools. In terms of effectiveness, direct patient 
intervention such as medication therapy management 
(MTM) was regarded as one of the most effective means for 
communicating with patients about potential risks and bene-
fits of therapy and already includes REMS-required compo-
nents in its framework. MTM is a personal consultation with 
a patient to ensure proper therapy, including pharmacologic 
and non-pharmacologic interventions. This patient-centered 
program allows healthcare providers to communicate with 
patients in order to identify problems with therapy, monitor 
the disease state and outcomes, follow-up with other profes-
sionals, and provide time for important education and coun-
seling. MTM tailors therapy around the patient and REMS 
could effectively be integrated into this intervention. Ideas 
were also put forth to combine MedGuides, consumer medi-
cation info, and patient package inserts into one easy to read 
document called patient medication information, which 
could be discussed during an MTM. 
Additionally, REMS programs, particularly those with 
ETASUs, need to include more input from providers during 
development This could be accomplished by conducting pi-
lot test REMS programs prior to implementation. With this, 
the program must also be flexible in order to reevaluate and 
adapt appropriately with post-marketing safety data. Stan-
dardized processes would permit more concise provider re-
sponsibilities. Drugs in similar classes or with similar risks 
would be managed in a comparable manner. 
Another important improvement stakeholders discussed was 
the ease of implementation into current workspace. REMS 
execution should be incorporated using existing technology 
and be integrated smoothly into workflow. An electronic re-
source or clearinghouse for all REMS information would sim-
plify the process and allow easy access to pertinent informa-
tion. Providers may also use a unique identifier, such as a 
National Provider Identifier (NPI), to track specific require-
ments needed to prescribe and dispense products requiring 
REMS. Offering stakeholders the opportunity to fulfill con-
tinuing education requirements with REMS specialized train-
ing would serve as an incentive for completion. 
Lastly, many complications exist in developing a compensa-
tion model. All stakeholders agreed that this issue must be 
addressed appropriately for the future. 
Pharmacist's Role 
Pharmacy practice is affected by the implementation of 
REMS. At the stakeholder meeting, pharmacists were ac-
knowledged for their importance in these risk management 
programs. Pharmacists can be up to date on all of the REMS 
requirements and can coordinate implementation activities 
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and responsibilities with other providers. As the drug ex-
perts, it is important for pharmacists to be aware and under-
stand what requirements physicians must comply with for 
specific REMS. Recently, to address the lack of standardiza-
tion issue, the FDA is requiring the creation of class-wide 
REMS programs for certain product families.a In demonstrat-
ing this, the large scaled long-acting and extended-release 
opioids REMS program will soon be effective as part of a plan 
to reduce prescription drug abuse. Pharmacists should be 
aware of what this program includes and how it · will affect 
their patients. In the hospital setting, pharmacists who serve 
on the Pharmacy and Therapeutics (P&T) Committee must 
know REMS components and understand how it affects for-
mulary inclusion for their hospital. Protocols, liability, fi-
nances, and outcomes are all important issues to address. 9.10 
Pharmacists will also have the opportunity to be integral 
players in MTM services for patients if these services are in-
corporated into the REMS framework, providing patient-
centered care and tailoring REMS safety issues to their thera-
pies. With the increasing number of REMS and prospects of 
an increased role of the pharmacist in MTM consultations, 
pharmacists and professional organizations must continue to 
advocate for MTM legislation, including a standard reim-
bursement model for these services. Advocacy for a REMS 
compensation model must also be addressed. 
Conclusion 
Risk management has evolved to include REMS programs 
designed to prevent or minimize serious adverse events 
when using certain medications. The inclusion of REMS af-
fects the pharmaceutical industry, health care providers, and 
patients. The current REMS model brings several concerns, 
and different stakeholders, organizations, and the FDA are 
looking to improve this system in the next few years. Phar-
macists will continue to play an integral role in patient care, 
and have to remain aware and active when it comes to imple-
menting REMS programs. Overall, REMS programs and asso-
ciated drug safety efforts from all health care stakeholders 
should continue to advance patient education, safety, and 
quality of care. 
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